Paper Details

  1. Home
  2. Paper Details

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

Author: AnugulruengkittSuvaporn, ChantaratinSasitorn, ChokephaibulkitKulkanya, JantarabenjakulWatsamon, KosalaraksaPope, MaleesatharnAlan, PhongsamartWanatpreeya, SirikuttPakpen, SuntarattiwongPiyarat

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the safety and efficacy of switching HIV-positive adolescents from efavirenz to rilpivirine-based antiretroviral therapy, assessing both immunologic and virologic outcomes over 48 weeks.
Paper Details　
Original Abstract of the Article :
Efavirenz (EFV) is commonly used for first-line antiretroviral therapy in children and adolescents with HIV, but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) is better tolerated, and switching from EFV to RPV in virologically suppressed adults has been safe and e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743364/

データ提供：米国国立医学図書館（NLM）

Switching from Efavirenz to Rilpivirine: A New Frontier in HIV Treatment for Adolescents

The field of [pediatric HIV care] is continually seeking ways to improve the [treatment and management] of [HIV] in adolescents. This [multi-centre study] investigated the safety and efficacy of switching from [efavirenz (EFV)] to [rilpivirine (RPV)] in [virologically suppressed adolescents] with [HIV]. The authors aimed to evaluate the [immunologic and virologic outcomes] of this switch, as well as the associated [neuropsychiatric adverse events, quality of life (QOL), and metabolic profiles] in adolescents treated with [RPV].

Rilpivirine: A Promising Alternative for Adolescents Living with HIV

The study's findings suggest that switching from [EFV] to [RPV] in [virologically suppressed adolescents] with [HIV] is both safe and effective. The authors observed a [maintained virologic suppression] and [favorable immunologic outcomes] in the adolescents switched to [RPV]. Moreover, [RPV] was associated with [fewer neuropsychiatric adverse events] and [improved QOL] compared to [EFV]. This research provides valuable evidence supporting the use of [RPV] as a [well-tolerated and efficacious] treatment option for [virologically suppressed adolescents] with [HIV].

A New Oasis in the Desert of HIV Care for Adolescents: Navigating Treatment Options

This research, like a refreshing oasis in the desert of [HIV care] for adolescents, highlights the potential of [RPV] as a safe and effective alternative to [EFV]. The findings suggest that [RPV] can provide a better-tolerated treatment option, improving the [quality of life] and reducing the risk of [neuropsychiatric side effects] in adolescents living with [HIV]. This knowledge empowers healthcare professionals to offer more individualized and patient-centered care to [adolescents with HIV], leading to improved outcomes and a brighter future for this population.

Dr.Camel's Conclusion

This research, like a guiding star in the desert of [HIV treatment] for adolescents, demonstrates the safety and efficacy of switching from [EFV] to [RPV]. The findings suggest that [RPV] can provide a better-tolerated and more effective treatment option, improving the quality of life and reducing the risk of side effects in adolescents living with [HIV].

Date :
  1. Date Completed 2022-01-24
  2. Date Revised 2022-01-24
Further Info :

Pubmed ID

35001501

DOI: Digital Object Identifier

PMC8743364

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.